Agios Pharmaceuticals
AGIO
208 hedge funds and large institutions have $4.29B invested in Agios Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 71 increasing their positions, 74 reducing their positions, and 30 closing their positions.
39% more capital inflows, than outflows
Capital inflows: $342M | Capital outflows: $245M
26% more call options, than puts
Call options by funds: $25.1M | Put options by funds: $19.8M
1.52% more ownership
Funds ownership: 94.46% → 95.99% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 74
4% less funds holding
Funds holding: 217 → 208 (-9)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$74.6M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$34.6M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$24.7M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$23.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$57.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$51.8M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$26.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.73M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.4M |
AGIO Hedge Fund Activity: Q3 2018 in Review
208 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2018, worth a combined $4.29B — down 6.4% from $4.58B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of AGIO and 23 opened new positions — a net loss of 7 holders — while 74 trimmed existing stakes and 71 added.
The largest buyer was Woodford Investment Management, adding an estimated $74.6M. The largest seller was Lord, Abbett & Co, cutting an estimated $57.2M.
- 208 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2018, down from 217 in Q2 2018.
- Funds reported $4.29B of Agios Pharmaceuticals stock for Q3 2018, down 6.4% quarter-over-quarter.
- 23 funds opened new Agios Pharmaceuticals positions in Q3 2018 and 30 closed out, a net change of -7 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2018 was Woodford Investment Management, an estimated $74.6M added.
- The largest Agios Pharmaceuticals seller in Q3 2018 was Lord, Abbett & Co, an estimated $57.2M sold.
Based on aggregated 13F filings for Q3 2018.